NCT06751082 Real World Observational Study of Sotatercept for Pulmonary Hypertension
| NCT ID | NCT06751082 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-01-20 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-01-20 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.
Eligibility Criteria
Inclusion Criteria: * Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic. Exclusion Criteria: * Adults lacking capacity to consent
Contact & Investigator
Robert Frantz, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06751082 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06751082 currently recruiting?
Yes, NCT06751082 is actively recruiting participants. Contact the research team at Halbach.Hayden@mayo.edu for enrollment information.
Where is the NCT06751082 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06751082 clinical trial?
NCT06751082 is sponsored by Mayo Clinic. The principal investigator is Robert Frantz, M.D. at Mayo Clinic. The trial plans to enroll 120 participants.